• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm

By: Schall Law via GlobeNewswire
November 27, 2025 at 09:40 AM EST

LOS ANGELES, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before December 8, 2025.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. aTyr and its executives expressed confidence about the forced taper study design for the Phase 3 trial of Efzofitimod. The Company concealed the drug’s capability to let patients taper their steroid usage completely. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about aTyr, investors suffered damages.

Join the case to recover your losses

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.        

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE:

 The Schall Law Firm


Primary Logo

More News

View More
News headline image
3 Stocks Poised to Benefit From Google’s AI Breakthough ↗
December 03, 2025
Via MarketBeat
Topics Artificial Intelligence
Tickers AVGO CLS GOOG GOOGL NVDA ORCL
News headline image
Beyond NVIDIA: 5 Semiconductor Stocks Set to Dominate 2026 ↗
December 03, 2025
Via MarketBeat
Tickers ADI AMD AVGO MRVL MU NVDA
News headline image
3 Stocks You’ll Wish You Bought Before 2026 ↗
December 03, 2025
Via MarketBeat
Tickers CELC DAVE TDUP
News headline image
Wall Street Punished CrowdStrike for Beating Earnings? Seriously? ↗
December 03, 2025
Via MarketBeat
Tickers CRWD
News headline image
Okta: Excuses to Sell Vs. Reasons to Buy ↗
December 03, 2025
Via MarketBeat
Tickers CRWD OKTA PANW ZS

Recent Quotes

View More
Symbol Price Change (%)
AMZN  232.38
+0.00 (0.00%)
AAPL  284.15
+0.00 (0.00%)
AMD  217.60
+0.00 (0.00%)
BAC  54.09
+0.00 (0.00%)
GOOG  320.62
+0.00 (0.00%)
META  639.60
+0.00 (0.00%)
MSFT  477.36
-0.37 (-0.08%)
NVDA  179.59
+0.00 (0.00%)
ORCL  207.73
+0.00 (0.00%)
TSLA  446.74
+0.00 (0.00%)
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap